Kura Oncology (NASDAQ:KURA) Announces Earnings Results

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43, Zacks reports.

Kura Oncology Price Performance

KURA traded down $0.11 on Wednesday, reaching $7.77. The company had a trading volume of 693,965 shares, compared to its average volume of 1,618,769. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The company has a market cap of $604.23 million, a price-to-earnings ratio of -3.29 and a beta of 0.78. The business has a 50 day simple moving average of $8.22 and a 200 day simple moving average of $13.96.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last quarter. Insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KURA. Scotiabank cut their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Jefferies Financial Group decreased their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $27.13.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.